David Parke, MD
Ophthalmology · Minneapolis, MNNPI 1265638746
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,710 of the $5,814 with a category attached, or 81.0%. Genentech USA, Inc. accounts for 81.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $2,371 and has fallen 98.1% since, to $45 in 2023.
Across 10 payments — averaging $581.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- Genentech, Inc.$950
- Carl Zeiss Meditec, Inc.$70
- Alcon Research LLC$45
- Novartis$23
- Alcon$16
Across 486 payments — averaging $9153.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3M
- Apellis Pharmaceuticals, Inc.$869K
- Novartis$358K
- Janssen Research & Development, LLC$142K
- Ocular Therapeutix, Inc.$75K
- AstraZeneca$13K
- plus $7K from 1 others
What the payments were for
- Consulting fees$4,71081%
- Travel & lodging$59410%
- Food & beverage$5109%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 2 | $4,710 |
| Genentech, Inc. | 4 | $950 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Alcon Research LLC | 1 | $45 |
| Novartis | 1 | $23 |
| Alcon | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucentis$4,710
- Non-Covered Product$950
How this compares
$5,814 in reported general payments places this provider in the 85th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 223 | $13,608 |
| Ketorolac Tromethamine | 248 | $4,949 |
| Brimonidine Tartrate | 56 | $1,787 |
| Difluprednate | 15 | $1,679 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 81 | $1,614 |
| Atropine Sulfate | 36 | $1,511 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 121 | $1,500 |
| Latanoprost | 136 | $1,337 |
| Dexamethasone Sodium Phosphate | 14 | $643 |
| Timolol Maleate | 50 | $597 |
| Dorzolamide Hcl | 21 | $407 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Minneapolis
- Edwin RyanMinneapolis$9.6M
- David HardtenMinneapolis$119K
- Sandra MontezumaMinneapolis$48K
- Sundeep DevMinneapolis$13K
- Silvia Orengo-NaniaMinneapolis$12K
- Robert MittraMinneapolis$6K
- Michael LeeMinneapolis$3K
- Huda SheheitliMinneapolis$3K
- Dinesh GoyalMinneapolis$3K
- Mark LobanoffSt Louis Park$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.